(Q48592996)

13 February 2018

title

The value of medical interventions for lung cancer in the elderly: results from SEER-CMHSF. (English)

1 reference

13 February 2018

4

Kathleen A Cronin

1 reference

13 February 2018

author name string

Rebecca M Woodward

1

1 reference

13 February 2018

Martin L Brown

2

1 reference

13 February 2018

Susan T Stewart

3

1 reference

13 February 2018

David M Cutler

5

1 reference

13 February 2018

language of work or name

English

0 references

publication date

1 December 2007

1 reference

13 February 2018

published in

Cancer

1 reference

13 February 2018

volume

110

1 reference

13 February 2018

issue

11

1 reference

13 February 2018

page(s)

2511-2518

1 reference

13 February 2018

Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Estimating health care costs related to cancer treatment from SEER-Medicare data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

One hundred years of lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Population variations in the initial treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Who gets chemotherapy for metastatic lung cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Economic issues in lung cancer: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Growth and quality of the cost-utility literature, 1976-2001.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

The evolution of treatment outcomes for resected stage IIIA non-small cell lung cancer over 16 years at a single institution

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Lung cancer and smoking trends in the United States over the past 25 years

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Patterns of adolescent smoking initiation rates by ethnicity and sex.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Economic issues in lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Economic considerations in the care of lung cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Non-small-cell lung cancer in a French department, (1982-1997): management and outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Evidence-Based Outcomes for Patients with Non-Small Cell Lung Cancer Undergoing Resection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Willingness to pay for a quality-adjusted life year: in search of a standard

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Significant progress in palliative treatment of non-small cell lung cancer in the past decade.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Adjuvant chemotherapy for lung cancer--a new standard of care

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Cigarette smoking and lung cancer trends. A light at the end of the tunnel?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23058

7 January 2021

Identifiers

DOI

10.1002/CNCR.23058

1 reference

13 February 2018

PubMed ID

17955504

1 reference

13 February 2018